Mirtazapine in drug-induced excessive sweating
University Department for Adult Psychiatrie, Lausanne, Switzerland.European Journal of Clinical Pharmacology (Impact Factor: 2.97). 09/2005; 61(7):543-4. DOI: 10.1007/s00228-005-0956-z
Excessive sweating is a well-known side effect of a selective serotonin reuptake inhibitor treatment, but little is known about the impact of sweating on treatment discontinuation or the general quality of life of patients. In this case report, we present a patient suffering from excessive sweating induced by escitalopram. When mirtazapine was administered as an additional treatment, a dose-dependent reduction of drug-induced excessive sweating was observed. Taking into account the particular serotonin antagonistic properties of mirtazapine, its eventual influence on the regulation of body temperature and diaphoresis in the central nervous system is discussed.
- Journal of Psychosocial Nursing and Mental Health Services 03/2007; 45(2):15-8. · 0.72 Impact Factor
- The Journal of Clinical Psychiatry 05/2007; 68(4):639-40. DOI:10.4088/JCP.v68n0423f · 5.50 Impact Factor
- American Journal of Psychiatry 08/2007; 164(7 Suppl):5-53. · 12.30 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.